Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q4 FY26 results · Jan–Mar 2026
Ajanta Pharma reported revenue from operations of ₹1,421.64 crore (up 21.5% from Q4 FY25) and net profit of ₹266.70 crore (up 18.4% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,421.64 | 1,170.41 | +21.5% | 1,374.84 | +3.4% |
| Other income | 61.43 | 18.11 | +239.2% | 24.97 | +146.0% |
| Total income | 1,483.07 | 1,188.52 | +24.8% | 1,399.81 | +5.9% |
| Profit before tax | 347.11 | 269.41 | +28.8% | 358.60 | −3.2% |
| Net profit for the period | 266.70 | 225.26 | +18.4% | 273.77 | −2.6% |
| EPS, basic (₹) | 21.35 | 18.00 | +18.6% | 21.91 | −2.6% |
| Net margin (%) | 18.8 | 19.2 | 19.9 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,210.53 | 1,013.94 | +19.4% | 1,206.59 | +0.3% |
| Other income | 62.98 | 17.93 | +251.3% | 25.76 | +144.5% |
| Total income | 1,273.51 | 1,031.87 | +23.4% | 1,232.35 | +3.3% |
| Profit before tax | 257.61 | 228.15 | +12.9% | 322.46 | −20.1% |
| Net profit for the period | 197.28 | 193.43 | +2.0% | 245.04 | −19.5% |
| EPS, basic (₹) | 15.79 | 15.46 | +2.1% | 19.61 | −19.5% |
| Net margin (%) | 16.3 | 19.1 | 20.3 |
Consolidated
- Filed with BSE
- 05 May 2026, 17:17 IST
- Board meeting
- 05 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 May 2026, 17:17 IST
- Board meeting
- 05 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE